Rucaparib is an orally active and potent inhibitor of polyadenosine diphosphate ribose polymerase (PARP). It is suitable for maintenance therapy of BRCA-mutated recurrent ovarian disease and BRCA-mutated metastatic castration-resistant prostate disease. The following will elaborate on the side effects caused by Rucaparib, the availability and interactions.

What side effects can Rucaparib cause?

Rucaparib has side effects, like any drug, which manifest themselves in the following ways.

Digestive system reactions

Nausea, vomiting, diarrhea, decreased appetite, indigestion.

Hematologic reactions

Anemia, elevated AST (aspartate aminotransferase)/ALT (alanine aminotransferase), thrombocytopenia, neutropenia, leukopenia.

Skin reactions

Photosensitivity reactions, rashes.

other

Fatigue, weakness, constipation.

After understanding the side effects of Rucaparib, let's take a look at the availability of Rucaparib.

What is the listing status of Rucaparib?

Rucaparib is currently not listed in the country, and here are the details:

Availability

Rucaparib was first approved for marketing by the US FDA on December 19, 2016. Since then, the drug has also been approved for marketing in many countries and regions such as the European Union and Japan. In China, the drug has not yet been approved for marketing.

Health insurance

Since Rucaparib is not yet available in China, it is not currently included in China's NRDL.

Generic drug situation

There are generic drugs for Rucaparib, and patients can follow the R&D progress and market dynamics of generic Rucaparib to learn about the latest product information.

After understanding the listing situation, let's take a look at what are the interactions?

Rucaparib's interactions?

There are several aspects to consider regarding drug interactions in Rucaparib, and the following is a detailed summary of drug interactions:

with gastric acid suppressants

Proton pump inhibitors (eg, omeprazole) and H2 receptor antagonists (eg, ranitidine), as well as some alkaline drugs (eg, antipyrine hydrochloride), may reduce Rucaparib absorption.

with liver enzyme inducers

For example, rifampicin and carbamazepine can accelerate the metabolism of Rucaparib and reduce its concentration in the body, thereby reducing its efficacy.

with liver enzyme inhibitors

Barbiturates and verapamil, for example, can inhibit the metabolism of Rucaparib and increase its concentration in the body, which may lead to an increase in the adverse effects of the drug.

with antibiotics

Quinolone antibiotics and Rucaparib interfere with each other to reduce plasma concentrations of Rucaparib.

with anticoagulant drugs

Concomitant use of Rucaparib, such as warfarin, may increase the risk of bleeding.

These interactions may affect the efficacy and safety of the drug, so it is important to follow your doctor's advice and pay close attention to drug reactions and side effects when using Rucaparib.